OncoMatch/Clinical Trials/NCT04634357
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Is NCT04634357 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies ET140203 T Cells for hepatoblastoma.
Treatment: ET140203 T Cells — Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: AFP expression (>100ng/mL)
serum AFP >100ng/mL at the time of screening and following the most recent line of therapy
Required: HLA-A a2 allele
Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject carries at least one HLA-A2 allele
Disease stage
Metastatic disease required
Metastatic Liver Cancer
Demographics
Prior therapy
Must have received: standard-of-care therapy
Disease recurrence after remission following initial standard-of care (SOC) treatment (i.e., relapse) or failure of response to SOC treatment (i.e., refractory)
Lab requirements
Liver function
child-pugh score of a6 or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital Los Angeles · Los Angeles, California
- Children's Hospital Orange County · Orange, California
- UCSF Benioff Children's Hospitals · San Francisco, California
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04634357 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard-of-care therapy.
Does this trial require AFP?
Yes, AFP expression is a required biomarker for enrollment.
Does this trial require HLA-A?
Yes, HLA-A a2 allele is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages